Study of Tazemetostat in Lymphoid Malignancies
Terminated · Phase 1 · NCT05983965
Conditions: T-cell Lymphoma
At a glance
- Research payments reported, 2025
- $211,014
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 6
About the trial
- Sponsor
- University of Alabama at Birmingham (with Robert Award, Epizyme, Inc.)
- Tested
- Tazemetostat (drug)
- Dates
- Started 2024-09-05; completion 2026-03-06
- Results posted
- Not yet
Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment option. We propose a study to evaluate the safety of tazemetostat in relapsed / refractory peripheral T-cell lymphoma.
From ClinicalTrials.gov, last updated 2026-04-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $211,014 in research payments for this study in 2025 (3 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.